PALB2 and neoplasm: The sensitivity of tumors with HRR mutations (HRRm), including BRCA1, BRCA2, PALB2, and RAD51C, to PARPi has been reported in preclinical research (14), as well as clinically (15, 16), across tumor types (Supplementary Table S1).